

SPRING GROUP MEETING

Seattle

Lymphoma Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON

Lymphoma Committee

Leadership

Chair: Jonathan W. Friedberg, MD
 Vice-Chair: Sonali M. Smith, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Michael LeBlanc, PhD
 Hongli Li, MS
 Shay Bellasea, MS

Scientific Leadership

Translational Medicine: Alexey Danilov, MD, PhD
 Radiation Oncology: Nicholas Burden Figura, MD
 Imaging: Lawrence H. Schwartz, MD
 Immunotherapeutics: Sweetha Kambhampati, MD
 Pathology: Joo Y. Song, MD
 Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Cancer Control: Hayder Saeed, MD
 Digital Engagement: Elizabeth A.G. Brem, MD
 Veterans Affairs: Helen Ma, MD
 Data Coordinators: Alex Rangel, BS
 Gabi Herbert, MS, BS
 Laura Wells, BA
 Daria Chugina, MD, CCRPS
 Oncology Research Professionals:
 CRA: Erin M. Cebula, MPH
 Nurse: TBD
 Patient Advocate: Hildy Dillon, MPH (Emeritus)
 Tricia Hernandez, MS
 Pharmaceutical Science: Holly O. Chan, PharmD
 Martina Fraga, PharmD
 Protocol Project Manager: Katarina Gasic
 Clinical Trials Program Manager: Crystal Miwa

Time/Location

Friday, April 5, 2024 2:15 p.m. - 4:15 p.m.
 Room: Elwha AB (Level 5)

Agenda

1. **Welcome:** Sonali Smith, MD
2. **Update on S1826:** Dr. Herrera
3. **Can We Cure Follicular Lymphoma?**
 - a. Legacy of S0016 Dr. Shadman
 - b. Opportunity of low tumor burden disease Dr. Friedberg
 - c. S2308 Dr. Ghosh

4. Committee Reports

- | | |
|-----------------------|-----------------|
| a. Patient Advocacy | Ms. Hernandez |
| b. Immunotherapeutics | Dr. Kambhampati |
| c. Cancer Control | Dr. Saeed |

5. Review of Selected Studies

- | | |
|-------------|--------------|
| a. S2207 | Dr. Amengual |
| b. S2114 | Dr. Hess |
| c. S1918 | Dr. Brem |
| d. S1608 | Dr. Barr |
| e. S1925 | Dr. Stephens |
| f. EA4151 | Dr. Till |
| g. AHOD2131 | Dr. Hu |
| h. AO51902 | Dr. Amengual |
| i. AO52101 | Dr. Phillips |
| j. ANHL1931 | Dr. Kamdar |

Proposed Studies

S2308, "Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma." Drs. Ghosh and Friedberg.

Open Studies

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Drs. Barr and Burack. Activated: 8/10/17.

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem and Smith. Activated: 3/19/21.

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. Hess and Hossain. Activated: 2/23/2023.

S2207, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. Amengual, Reagan, and Smith. Activated: 6/30/2023

CTS/EA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients

Lymphoma Committee

with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission." Dr. Fenske. SWOG Champion: Dr. Till. Activated: 8/29/17.

CTSU/ANHL1931, "A Randomized Phase 3 trial of Nivolumab in Combination with Chemo immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B cell Lymphoma." Dr. Roth. SWOG Champion: Dr. Kamdar. Activated 6/7/2021.

CTSU/A051902, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Mehta-Shah. SWOG Champion: Dr. Amengual. Activated 7/30/2021.

CTSU/A052101, "A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)." Dr. Beaven. SWOG Champion: Dr. Tycel. Activated 09/08/2023.

CTSU/AHOS2131, "A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma." Dr. Henderson. SWOG Champion: Dr. Hu. Activated 04/28/2023.

Closed Lymphoma Studies

CTSU/A051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. Vallurupalli. Activated: 8/7/19. Closed: 12/14/2023.

CTSU/EA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients \leq 70 years Old with Untreated Mantle Cell Lymphoma." Dr. Wagner-Johnson. SWOG Champion: Dr. Spurgeon. Activated: 10/3/19. Closed: 4/7/2023

Open Leukemia Studies

S1925, "A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Dr. Stephens. Activated: 12/14/20.

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. Advani and Papadantonakis. Activated: 8/17/20.

Open Cancer Care Delivery Study

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Shankaran. Activated 7/26/2021.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

Multiple Studies* Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Herrera A, Friedberg JW, Friedman D, Schwartz C, Pi Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. *JAMA Network Open* Jan 2;7(1):e2351062., 2024. [*S1826 and other] <https://pubmed.ncbi.nlm.nih.gov/38241048/>

Submitted Manuscripts

C51101 Myeloablative Versus Non-Myeloablative Consolidation for Newly Diagnosed Primary CNS Lymphoma: Results of Alliance 51101. Batchelor T, Giri S, Ruppert A, Geyer S, Smith S, Mohile N, Swinnen L, Friedberg JW, Kahl B, Bartlett N, Hsi E, Cheson B, Wagner-Johnston N, Nayak L, Leonard J, Rubenstein J.. Submitted 2023.

Lymphoma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1608	S1826	S1918	S2114	S2207	A051301	A051701	A051902	AH02131
Ascension Providence Hospitals - Southfield	-	5	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	2	-	-	-	-	1	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	3	1	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	1	-	-	-
Boston Medical Center	-	3	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	1	-	-	-	8	-	-
Cancer Research Consortium of West Michigan NCORP	3	13	-	3	-	-	-	-	1
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	2	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	3	1	-	1	-	-	-	-
City of Hope Comprehensive Cancer Center	8	21	8	-	-	1	-	-	6
Columbia University Minority Underserved NCORP	-	2	4	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	1	2	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	4	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	3	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	1	-
Georgia Cares Minority Underserved NCORP	-	6	2	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	2	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	20	-	-	-	-	-	-	-
Henry Ford Hospital	-	8	-	-	-	-	2	-	-
Kaiser Permanente NCI Community Oncology Research Program	3	11	2	-	-	-	-	-	-
King Faisal Specialist Hospital and Research Centre	-	-	-	-	-	4	-	-	-
Loyola University Medical Center	-	8	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	2	19	3	11	-	-	3	-	-
Michigan Cancer Research Consortium NCORP	1	6	4	-	-	-	-	-	-
Moffitt Cancer Center	-	15	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	8	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	11	-	-	-	-	-	-	-

Lymphoma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1608	S1826	S1918	S2114	S2207	A051301	A051701	A051902	AH02131
Nevada Cancer Research Foundation NCORP	-	2	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	1	-	-
Northwestern University LAPS	1	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	4	-	1	-	-	2	-	-
Pacific Cancer Research Consortium NCORP	-	7	-	4	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	6	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	18	-	-	-	-	4	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	3	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	8	-	-	-	-	-	-	-
Uof Alabama at Birmingham / Deep South Research Consortium LAPS	-	12	-	-	-	-	3	-	-
University of Arkansas for Medical Sciences	-	1	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	9	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	4	-	-	-	1	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	2	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	1	-	-	-	-	-	-	-
University of Rochester LAPS	16	33	-	4	2	3	11	-	4
University of Texas Health Science Center at San Antonio	-	17	-	2	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	3	34	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	14	3	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	1	7	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	4	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	11	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	7	-	-	-	-	-	-	-
ALLIANCE	16	134	29	3	-	-	-	-	-
CCTG	-	30	-	-	-	-	-	-	-
COG	-	313	-	-	-	-	-	-	-
ECOG-ACRIN	5	83	14	-	-	-	-	-	-
NRG	11	51	5	-	-	-	-	-	-
Total	77	994	83	28	4	12	34	1	11

Lymphoma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	ANHL1931	E4412	EA4151	EA4181
Ascension Providence Hospitals - Southfield	-	-	-	-
Banner University Medical Center - Tucson	-	-	1	2
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-
Boston Medical Center	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	17	14
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-
City of Hope Comprehensive Cancer Center	6	-	18	-
Columbia University Minority Underserved NCORP	1	1	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	14	-
Georgia Cares Minority Underserved NCORP	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Hospital	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	11	-	12
King Faisal Specialist Hospital and Research Centre	-	-	-	-
Loyola University Medical Center	-	-	3	-
Medical University of South Carolina Minority Underserved NCORP	-	-	2	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Moffitt Cancer Center	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	1	-	2	-

Lymphoma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	ANHL1931	E4412	EA4151	EA4181
Nevada Cancer Research Foundation NCORP	-	1	-	-
Northwell Health NCORP	-	-	-	-
Northwestern University LAPS	1	-	-	-
Oregon Health and Science University	-	-	6	5
Pacific Cancer Research Consortium NCORP	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	1	-	-	-
UC San Diego Moores Cancer Center	-	-	1	-
University of Alabama at Birmingham / Deep South Research Consortium LAPS	-	7	5	-
University of Arkansas for Medical Sciences	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	2	3
University of Colorado Cancer Center LAPS	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	1
University of Kentucky/Markey Cancer Center	-	-	2	-
University of Mississippi Medical Center	-	-	-	-
University of Rochester LAPS	5	-	10	18
University of Texas Health Science Center at San Antonio	-	-	13	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	18	12
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1	6
Wisconsin NCI Community Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	5	-
ALLIANCE	-	-	-	-
CCTG	-	-	-	-
COG	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	15	20	120	73

